Aetion closes on $27M extension of series B financing to expand its real-world evidence platform

Cisco has announced a range of new data center offerings (Image CasarsaGuru / iStockPhoto)
Real-world data software developer Aetion closes $27 million extension of series B financing, bringing the total it has raised in the round to expand its platform to $63 million. (CasarsaGuru/iStockPhoto)

Real-world data software developer Aetion closed on a $27 million extension of series B financing, bringing the total raised in the round to expand its platform to $63 million.

Investors in the attest funding included Sanofi, Horizon Health Services (part of Blue Cross Blue Shield of New Jersey), UCB and McKesson Ventures, the company said.

Aetion’s evidence platform is used by eight of the top 15 global biopharma firms, leading payers and the FDA, which recently announced a new framework to use real-world data for regulatory approvals.

The company said the money will be used to support and enhance its platform specifically for “extending its reach in therapeutic area-related intelligence, outcomes-based contracting for payers and advancing the acceptance of standards for real-world evidence around the globe.”

"The time for real-world evidence is now," Carolyn Magill, Aetion’s chief executive, said in a statement. “We're entering a new era in which nearly the entire healthcare ecosystem—from biopharma and regulators to payers and technology companies—recognizes the importance of using real-world evidence to reduce the time and cost to bring new therapies to market."

The passage of the 21st Century Cures Act spurred growing interest in the use of real-world data for drug development and regulatory processes. Aetion uses rapid-cycle analytics technology to generate evidence from all kinds of data in any format, including claims, electronic medical records, patient-reported outcomes and registry data, as well as randomized clinical trial data.

Read more on

Suggested Articles

As the pandemic rages on and clinical trials are becoming increasingly siteless, eSource trial firm Clinical Ink has become an M&A target.

Pfizer has always been a heavy user of CROs, and over the past few months it’s been ramping up its partnerships.

Covance’s sales fell into the red this quarter as LabCorp’s CRO unit continues to battle major pandemic headwinds.